Skip to main content

Table 6 Sensitivity analyses of NashTest for the diagnosis of Nash versus No Nash or Borderline Nash [Area under the ROC curves (AUROCs)], according to group, ALT values, alcohol consumption, quality of biopsy, inclusion of patients without steatosis, and exclusion of high risk of biomarkers failures.

From: Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease

Characteristic of patients n NashTest AUROC Lower 95% Upper 95% Prevalence NASH Significance between AUROCs
All 257 patients 257 0.75 0.67 0.82 0.25  
Stratified according to Group*       
Training Group 160 0.79 0.69 0.86 0.18 0.94
Validation Group 97 0.79 0.67 0.87 0.36  
Stratified according to ALT value*       
ALT < 50 IU/L 92 0.78 0.58 0.89 0.17 0.58
ALT >= 50 IU/L 165 0.73 0.64 0.81 0.28  
Stratified according to Alcohol consumption*       
None 95 0.72 0.57 0.82 0.31 0.78 and 0.28
< 30 g for men and < 20 g for female 150 0.77 0.66 0.84 0.19 0.78 and 0.33
>= 30 g for men or >= 20 g for female 12 0.94 0.53 0.99 0.50 0.28 and 0.33
Quality of biopsy*       
< 25 mm 194 0.76 0.66 0.83 0.25 0.72
>= 25 mm 63 0.73 0.55 0.84 0.24  
Fragmented 148 0.71 0.58 0.80 0.22 0.15
Not Fragmented 109 0.81 0.70 0.88 0.28  
Patients included or excluded       
Patients without steatosis included** 277 0.76 0.68 0.82 0.39 0.85
High risk of NashTest failures excluded**       
Gilbert excluded 244 0.76 0.68 0.82 0.25 0.78
Acute Inflammation excluded 254 0.75 0.67 0.82 0.24 0.95
  1. * Comparison between stratified groups
  2. ** Comparison with all 257 patients